TopgOptions

ARDS 1250% upside potential according to H.C. Wainwright !!!

Long
NASDAQ:ARDS   None
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."

Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!

Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."

ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.

It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.

Market Cap of only 21.22Mil

52 Week Range 1.49 - 8.47

You can buy the all time low now!

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.